CRYSSA 2012.

Methods	Randomized controlled trial.
Participants	300 consecutive people undergoing isolated off‐pump CABG for stable coronary artery disease who received ≥ 1 SVG.
Interventions	Clopidogrel 75 mg plus aspirin 100 mg (n = 150; mean age (± SD) 59.4 ± 7.7 years; male sex 73.3%) for 12 months. Aspirin 100 mg (n = 150; mean age (± SD) 58.9 ± 8.3 years; male sex 75.3%) for 12 months.
Outcomes	Primary: response to platelet inhibition after off‐pump CABG. Secondary: graft occlusion at 12 months; major and minor bleeding (defined according to the CURE trial); and incidence of MACCEs (composite endpoint including cardiac deaths, any repeat revascularization (percutaneous coronary interventions or CABG), cerebrovascular accident and documented MI).
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Patients ... were randomly assigned to aspirin alone or double antiplatelet treatment by a computer‐generated algorithm and antiplatelet therapy was initiated."
Allocation concealment (selection bias)	Low risk	"Randomisation was fully blinded without taking account of clinical or demographic features."
Blinding (performance bias and detection bias) All outcomes	High risk	"The CRYSSA trial is a prospective randomised controlled study." No placebo used.
Incomplete outcome data (attrition bias) All outcomes	Low risk	The principal investigator (Dr Mannacio) provided additional data.
Selective reporting (reporting bias)	Unclear risk	No protocol available.
Other bias	Unclear risk	No data on funds.